Catalog No.
Product Name
Application
Product Information
Citations
-
FLT3/FLT3-ITD Inhibitor
FLT3/ITD-IN-5 is a potent inhibitor of FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is designed for use in cancer research, providing valuable insights into therapies targeting FLT3 mutations commonly found in acute myeloid leukemia (AML). Its high selectivity makes it an essential tool for studying FLT3 signaling pathways and developing targeted treatments. -
FLT3-ITD Inhibitor
FLT3/ITD-IN-4 is a selective inhibitor of FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD), exhibiting an IC50 of 2.3 nM. This compound demonstrates potent biological activity against FLT3-ITD mutations, making it valuable for research in acute myeloid leukemia. FLT3/ITD-IN-4 is ideal for studies exploring targeted therapies and the underlying mechanisms of FLT3-mediated signaling. -
FLT3 Receptor Antagonist
BDT001 is a selective FLT3 receptor antagonist that inhibits the signaling pathways associated with FLT3 activation. This compound demonstrates significant potential in research applications focused on pain disorders, cancer, and autoimmune diseases by modulating the activity of FLT3, a receptor implicated in cellular proliferation and survival. BDT001 serves as a valuable tool for investigating therapeutic strategies targeting FLT3-related pathologies. -
BTK/FLT3 Inhibitor
RSH-7 is a potent inhibitor of Bruton's tyrosine kinase (BTK) and Fms-like tyrosine kinase 3 (FLT3), exhibiting IC50 values of 47 nM and 12 nM, respectively. This compound induces apoptosis and demonstrates significant antiproliferative activity. By inhibiting BTK and FLT3 signaling pathways, RSH-7 is a valuable tool for research in oncology and targeted therapies for hematological malignancies. -
FLT3 Inhibitor
FLT3-IN-26 is a potent FLT3 inhibitor with a pIC50 value of 7.367. This compound demonstrates significant biological activity against FLT3, making it a valuable tool for investigating acute myeloid leukemia. Its specificity and efficacy facilitate research into targeted therapies for this malignancy. -
FLT3 Inhibitor
FLT3-IN-12 is a selective and orally bioavailable inhibitor of the FLT3 kinase, demonstrating IC50 values of 1.48 nM for FLT3-WT and 2.87 nM for the FLT3-D835Y mutant. This compound exhibits exceptional selectivity over c-KIT, surpassing 1000-fold. Additionally, FLT3-IN-12 showcases potent anti-acute myeloid leukemia (AML) activity, with an IC50 of 0.75 nM against the MV4-11 cell line, making it a valuable tool for the study of FLT3-driven malignancies and potential therapeutic applications in AML. -
FLT3 Inhibitor
FLT3-IN-15 is a potent and orally bioavailable inhibitor of the FLT3 receptor, exhibiting IC50 values of 0.87 nM for FLT3 and 0.32 nM for the FLT3/D835Y mutant. This compound is primarily utilized in research related to acute myeloid leukemia, providing insights into the therapeutic potential of targeting aberrant FLT3 signaling pathways in cancer treatment. -
FLT3 inhibitor
FLT3-IN-23 is a potent inhibitor of the Fms-like tyrosine kinase 3 (FLT3), exhibiting an IC50 value of 7.42 nM. It demonstrates significant antiproliferative activity against BaF3 cells harboring multiple FLT3 tyrosine kinase domain (TKD) and internal tandem duplication (ITD) mutations. This compound serves as a valuable tool for research in targeted therapies for FLT3-mutant leukemias. -
TRK Inhibitor
TRK II-IN-1 is a selective type II TRK inhibitor, exhibiting IC50 values of 3.3, 6.4, 4.3, and 9.4 nM against TRKA, TRKB, TRKC, and the TRKAG667C mutant, respectively. Additionally, it demonstrates inhibitory activity against FLT3, RET, and VEGFR2 with IC50 values of 1.3, 9.9, and 71.1 nM, respectively. This compound is valuable for research into TRK-driven cancers and related signaling pathways. -
FLT3/D835Y Inhibitor
FLT3/D835Y-IN-1 is a potent and selective inhibitor targeting FLT3 and the FLT3/D835Y mutant with IC50 values of 0.26 nM and 0.18 nM, respectively. This orally active compound demonstrates significant inhibition of tumor growth and exhibits anticancer efficacy, making it a valuable tool for research into acute myeloid leukemia (AML). FLT3/D835Y-IN-1 provides a targeted approach for studying the effects of FLT3 mutations in cellular and animal models of AML. -
FLT3 Inhibitor
CHEMBL4444839 is a potent FLT3 inhibitor that plays a crucial role in the study of acute myeloid leukemia (AML). Its ability to selectively target FLT3 makes it a valuable tool for investigating the molecular mechanisms of AML and developing potential therapeutic strategies. Researchers can leverage CHEMBL4444839 to explore the effects of FLT3 inhibition on cell proliferation and survival in AML models. -
PDGFRα/FLT3 Inhibitor
PDGFRα/FLT3-ITD-IN-1 is a selective inhibitor of the platelet-derived growth factor receptor alpha (PDGFRα) and the Fms-like tyrosine kinase 3 (FLT3), demonstrating IC50 values of 0.036 μM and 0.003 μM, respectively. This compound is particularly relevant for investigations into acute myeloid leukemia (AML) and chronic eosinophilic leukemia (CEL), providing a valuable tool for exploring therapeutic strategies targeting these malignancies. Researchers utilizing PDGFRα/FLT3-ITD-IN-1 can gain insights into the molecular mechanisms underlying these hematological disorders. -
FLT3 Inhibitor
FLT3-IN-18 is a highly selective inhibitor of FLT3, exhibiting an IC50 value of 0.003 μM. This compound effectively induces apoptosis and enforces G1 phase cell cycle arrest in FLT3-positive cells. Additionally, FLT3-IN-18 inhibits both FLT3 and STAT5 phosphorylation, making it a valuable tool for investigating the signaling pathways involved in acute myeloid leukemia (AML). Its potency and specificity position FLT3-IN-18 as a crucial reagent for researching FLT3-driven malignancies. -
FLT3 Inhibitor
TTT 3002 is a potent FLT3 inhibitor that effectively targets FLT3 phosphorylation in the presence of activating mutations at residue D835, demonstrating an IC50 of 0.2 nM. This compound is valuable for research in acute myeloid leukemia (AML) and other related hematologic malignancies. Its specificity and efficacy make it a crucial tool for investigating FLT3 signaling pathways and developing targeted therapies. -
FLT3/ITD Mutation Inhibitor
HP1142 is a selective inhibitor of the FLT3 receptor tyrosine kinase, specifically targeting the FLT3/ITD mutation. This compound, derived from a benzoimidazole scaffold, demonstrates significant efficacy in inhibiting FLT3 signaling pathways. HP1142 is primarily utilized in research focused on FLT3/ITD mutated leukemia, providing valuable insights into therapeutic strategies for this malignancy. -
FLT3/CDK4 Inhibitor
FLT3/CDK4-IN-1 is a highly selective, orally active dual inhibitor targeting FLT3 and CDK4, demonstrating IC50 values of 11 nM and 7 nM, respectively. This compound exhibits significant antiproliferative activity against specific cancer cell lines and shows promising antitumor effects in vivo. FLT3/CDK4-IN-1 is suitable for research applications focused on cancer biology, particularly in exploring pathways associated with leukemias and solid tumors. -
PDGFRα/FLT3 Inhibitor
PDGFRα/FLT3-ITD-IN-2 is a selective inhibitor targeting PDGFRα and FLT3, exhibiting IC50 values greater than 20 μM and 1.654 μM, respectively. This compound demonstrates significant biological activity relevant to the treatment of acute myeloid leukemia and chronic eosinophilic leukemia. Its efficacy in modulating these pathways makes it a valuable tool for investigational research in cancer therapeutics. -
PDGFR/TEL-PDGFR/FLT3/KIT Inhibitor
AGL 2043 is a potent inhibitor of PDGFR, TEL-PDGFR, FLT3, and KIT kinases, exhibiting an IC50 value of 0.8 μM against PDGFR. This compound demonstrates significant biological activity by effectively reducing porcine cardiac smooth muscle cell proliferation and mitigating balloon-induced vascular stenosis. AGL 2043 presents promising applications in the development of anti-restenotic and anticancer therapies. -
FLT3/IRAK1/4 Inhibitor
NCGC1481 is a potent inhibitor of FLT3, IRAK1, and IRAK4, displaying IC50 values of <0.5 nM, 22.6 nM, and 0.8 nM, respectively. This compound effectively mitigates the adaptive resistance of leukemia cells to FLT3 inhibitors, demonstrating significant antileukemic activity. NCGC1481 is suitable for research focused on leukemia treatment and the modulation of key signaling pathways involved in cancer cell survival and proliferation. -
FLT3 Inhibitor
Flt-3 Inhibitor III is a selective inhibitor of the FLT3 kinase with a potent IC50 value of 50 nM. This compound demonstrates minimal activity against other kinases, thereby ensuring specificity. Flt-3 Inhibitor III is primarily utilized in research applications related to cancer biology, particularly in studies investigating FLT3 mutations in acute myeloid leukemia (AML). Its ability to inhibit FLT3 activity underscores its potential as a therapeutic agent in targeted cancer therapies. -
MERTK/FLT3 Inhibitor
MRX-2843 hydrochloride is an orally active, ATP-competitive inhibitor targeting MERTK and FLT3 tyrosine kinases. It demonstrates potent enzymatic inhibitory activity with IC50 values of 1.3 nM for MERTK and 0.64 nM for FLT3. This compound is ideal for research applications investigating cancer therapies and related signaling pathways involving these kinases. -
FLT3 Inhibitor
AAE871 is a potent type I FLT3 inhibitor, exhibiting an IC50 value of 0.034 µM. It demonstrates significant biological activity in inhibiting FLT3 signaling, making it a valuable tool for investigating acute myeloid leukemia (AML) and related hematological malignancies. AAE871 is useful in preclinical studies aimed at understanding FLT3-mediated pathways and their role in cancer progression. -
FLT3 Inhibitor
FLT3-IN-38 is a selective FLT3 inhibitor that targets the FLT3 receptor tyrosine kinase, which is implicated in hematologic malignancies. This compound also exhibits off-target effects by inhibiting serine/threonine kinase haspin, a critical regulator of mitotic signaling. FLT3-IN-38 is suitable for cancer research applications, particularly in studies focused on the treatment of FLT3-mutated leukemias. -
IGF2BP1 Inhibitor
IGF2BP1-IN-1 is a selective inhibitor of the insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1). It demonstrates potent inhibition of IGF2BP1 with a dissociation constant (KD) of 2.88 nM and effectively suppresses cancer cell proliferation, exhibiting IC50 values of 9 nM in A549 cells and 34 nM in HCT116 cells. Additionally, IGF2BP1-IN-1 induces apoptosis in cancer cells and has been shown to inhibit tumor growth in A549 xenograft mouse models, making it a valuable tool for cancer research and therapeutic development targeting IGF2BP1-mediated pathways. -
IGF2BP3 Inhibitor
IGF2BP3-IN-1 is an inhibitor of IGF2BP3, a RNA-binding protein essential for regulating various cellular processes. With an IC50 value greater than 50 μM, this compound is primarily utilized in cancer research to explore the role of IGF2BP3 in tumor growth and progression. Its application extends to studies investigating the influence of RNA binding proteins on gene expression and potential therapeutic pathways in oncology. -
ALK Tyrosine Kinase Inhibitor
Ceritinib-d7 is a deuterium-labeled derivative of Ceritinib, which functions as a selective and ATP-competitive inhibitor of the ALK (anaplastic lymphoma kinase) tyrosine kinase. This compound is utilized in research to explore mechanisms of ALK-mediated oncogenesis and to evaluate the therapeutic efficacy of targeted treatments in malignancies such as non-small cell lung cancer. Its deuterium labeling allows for advanced studies in pharmacokinetics and metabolism, making it a valuable tool for chemical biology investigations. -
IGF-1R Inhibitor
NVP-AEW541 dihydrochloride is a potent inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), exhibiting an IC50 value of 0.15 μM. This compound also demonstrates inhibition of the insulin receptor (InsR) with an IC50 value of 0.14 μM. NVP-AEW541 dihydrochloride is recognized for its antitumor activity, making it a valuable tool for cancer research and therapeutic investigations targeting IGF signaling pathways. -
ALK Inhibitor
ALK-IN-24 is a potent, orally active inhibitor of anaplastic lymphoma kinase (ALK) with an IC50 value of 1.7 nM, also exhibiting inhibition of insulin receptor kinase with an IC50 value of 6 nM. It effectively suppresses the proliferation of lung adenocarcinoma cells and has demonstrated the ability to inhibit ALK-driven tumor growth in xenograft mouse models. This compound is applicable for research focused on non-small cell lung cancer and other ALK-related malignancies. -
Insulinotropic Polypeptide
Gastric Inhibitory Polypeptide (1-30), porcine is an insulinotropic polypeptide that enhances the secretion of insulin and somatostatin. This truncated form, missing the C-terminal 12 amino acids of the natural GIP, maintains key biological activity, making it valuable for research in glucose metabolism and endocrine function. It is particularly useful in studies examining the role of incretin hormones in insulin regulation. -
IGF-1R/InsR Inhibitor
AZD9362 is a reversible, ATP-competitive inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR). It exhibits potent biological activity with an IC50 of 14 nM for IGF-1R inhibition, making it suitable for cancer research applications. This compound has been shown to enhance the anti-tumor efficacy of AZD5363, presenting significant potential in the study of various cancers, including breast cancer. -
ALK/IR/VEGFR2/TIE2/DLK Inhibitor
CEP-14083 is an ATP-competitive inhibitor targeting ALK, with IC50 values of 2 nM in enzymatic assays. This compound also inhibits other kinases, including the insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2), and dual leucine zipper kinase (DLK). CEP-14083 has been shown to suppress CD274 mRNA expression and the function of NPM/ALK in NPM/ALK-positive T cell lymphoma cells. It is a valuable tool for research focused on lymphoma and related signaling pathways. -
PLK4 Inhibitor
CZS-241 is a selective Polo-like Kinase 4 (PLK4) inhibitor, exhibiting an IC50 of 2.6 nM. In addition to its primary activity, CZS-241 also inhibits TRKA with an IC50 of 2.74 μM. This compound induces apoptosis and effectively arrests the cell cycle at the S/G2 phase. CZS-241 demonstrates potent antiproliferative effects against leukemia cell lines while maintaining safety profiles in normal cell lines, making it a valuable tool for cancer research. -
c-Met/HDAC Inhibitor
c-Met/HDAC-IN-3 is a dual inhibitor targeting c-Met and histone deacetylase 1 (HDAC1), exhibiting IC50 values of 12.50 nM and 26.97 nM, respectively. This compound demonstrates significant biological activity by inducing apoptosis and causing cell cycle arrest at the G2/M phase. c-Met/HDAC-IN-3 serves as a valuable tool for research in cancer biology and therapeutic development, particularly in studies focused on synergistic inhibition of oncogenic pathways. -
TrkA Receptor Agonist
BNN27 is a selective agonist of the TrkA and p75NTR receptors, demonstrating significant neurotrophic and anti-apoptotic activity. This compound enhances the levels of key neurotransmitters, including glutamate, GABA, and glutamine, in rat hippocampal and prefrontal cortical tissues, thereby improving glutamate turnover. BNN27 has shown neuroprotective effects in a mouse model of amyotrophic lateral sclerosis (ALS), anti-inflammatory properties in experimental autoimmune encephalomyelitis (EAE), and retinal protective efficacy in diabetic rat models. Additionally, BNN27 is capable of crossing the blood-brain barrier, making it a valuable tool for neurological research. -
Mer/c-met Inhibitor
Mer/c-Met-IN-1 is a potent dual inhibitor targeting Mer and c-Met with IC50 values of 1 nM and 19 nM, respectively. This compound effectively inhibits cancer cell proliferation and migration while inducing apoptosis. Mer/c-Met-IN-1 is valuable for research into various cancers, including colon cancer, providing insights into therapeutic strategies and mechanisms of action. -
VEGFR-2 Inhibitor
VS 8 is a potent oral inhibitor of the vascular endothelial growth factor receptor 2 (VEGFR-2), exhibiting significant anti-angiogenic properties. This compound promotes apoptosis in cancer cells and inhibits cellular migration, making it relevant for studies targeting tumor progression. Additionally, VS 8 demonstrates activity against cancer stem cells (CSCs), providing insights for research in cancer treatment and therapeutic resistance. -
TRK Inhibitor
JND4135 is a Type II TRK inhibitor that effectively targets TRKA, TRKB, and TRKC with IC50 values of 2.79, 3.19, and 3.01 nM, respectively. This compound is capable of overcoming resistance associated with TRK xDFG and other mutant forms, inhibiting the phosphorylation of both wild-type and mutant TRKs, as well as their downstream signaling pathways. JND4135 induces G0/G1 phase cell cycle arrest and apoptosis in BaF3–CD74-TRKA-G667C cells and exhibits potent antitumor activity in a BaF3-CD74-TRKA-G667C mouse xenograft model, highlighting its potential for cancer research and therapy. -
FLT3 Inhibitor
FLT3-IN-14 is a potent inhibitor of the FLT3 receptor, exhibiting IC50 values of 5.6 nM for wild-type FLT3 and 1.4 nM for the FLT3-ITD mutant. This compound effectively reduces the phosphorylation of FLT3 at Y591, leading to cell cycle arrest in the G1 phase and subsequent induction of apoptosis. In preclinical studies, FLT3-IN-14 has demonstrated significant efficacy in reducing tumor growth within MV4-11 xenograft mouse models, highlighting its potential for therapeutic applications in FLT3-related malignancies. -
EGFR/HER2/TS Inhibitor
EGFR/HER2/TS-IN-1 is a selective inhibitor targeting EGFR, HER2, and thymidylate synthase (TS) with IC50 values of 0.203 μM, 0.088 μM, and 0.168 μM, respectively. This compound is effective in inducing apoptosis in MCF7 breast cancer cells, making it a valuable tool for cancer research. Its ability to simultaneously inhibit multiple targets renders it a promising candidate for exploring therapeutic strategies in malignancies characterized by overactive EGFR and HER2 signaling pathways. -
FGFR4 Inhibitor
FGFR4-IN-7 is a covalent reversible inhibitor of Fibroblast Growth Factor Receptor 4 (FGFR4), exhibiting an IC50 of 0.42 μM. This compound disrupts the FGFR4 signaling pathway, leading to the induction of apoptosis. FGFR4-IN-7 is primarily utilized in research focused on hepatocellular carcinoma (HCC) and offers potential insights into therapeutic strategies targeting this malignancy. -
EGFR Inhibitor
EGFR-IN-150 is a potent inhibitor of the epidermal growth factor receptor (EGFR), effectively blocking phosphorylation of mutant EGFR and downstream AKT signaling, leading to antitumor activity. This compound demonstrates an IC50 of 0.386 μM in the non-small cell lung cancer (NSCLC) cell line H1975, significantly reducing colony formation and migration in both H1975 and A549 cells while promoting apoptosis. Furthermore, EGFR-IN-150 exhibits substantial tumor growth suppression in the H1975 cell-derived xenograft (CDX) mouse model, making it a valuable tool for research focused on non-small cell lung cancer. -
EGFR Inhibitor
Erbstatin is an inhibitor of the epidermal growth factor receptor (EGFR), targeting its kinase activity to impede downstream signaling pathways. This compound exhibits significant antineoplastic properties, making it a valuable reagent in cancer research. Erbstatin is utilized in studies investigating the role of EGFR in tumor progression and response to therapy, providing insights into potential treatment strategies for EGFR-mediated malignancies. -
Tubulin/VEGFR Inhibitor
Tubulin/VEGFR-2-IN-2 is an orally active inhibitor targeting tubulin and VEGFR-2, exhibiting IC50 values of 3.27 μM and 0.09 μM, respectively. This compound demonstrates significant antitumor activity by enhancing reactive oxygen species generation, disrupting mitochondrial membrane potential, inducing apoptosis, and arresting the cell cycle. Additionally, Tubulin/VEGFR-2-IN-2 possesses anti-angiogenic effects, impairing endothelial cell migration, invasion, and tube formation in vitro. It effectively suppresses angiogenesis, tumor growth, and metastasis in vivo, making it a valuable tool for research involving non-small cell lung cancer, breast cancer, gastric cancer, and lymphoma. -
c-Met/HDAC Inhibitor
c-Met/HDAC-IN-2 is a highly potent dual inhibitor targeting c-Met and histone deacetylases (HDACs), exhibiting IC50 values of 18.49 nM for HDAC1 and 5.40 nM for c-Met. This compound demonstrates significant antiproliferative effects against various cancer cell lines, notably inducing G2/M-phase cell cycle arrest and apoptosis in HCT-116 cells. c-Met/HDAC-IN-2 is a valuable tool for investigating mechanisms of anti-cancer resistance and exploring therapeutic strategies in oncology research. -
Multikinase Inhibitor
Multi-kinase-IN-6 is a potent multikinase inhibitor targeting TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. It demonstrates significant antiproliferative effects in cancer cell lines, with IC50 values of 3.36 μM for MCF7, 1.40 μM for HCT116, and 3.49 μM for EKVX. Furthermore, Multi-kinase-IN-6 induces cell cycle arrest at the G1/S phase and G1 phase in MCF7 and HCT116 cells while promoting apoptosis, making it a valuable tool for cancer research and therapeutic studies. -
FGFR/HDAC Inhibitor
HDAC-IN-50 is a potent dual inhibitor targeting FGFR and HDAC with IC50 values of 0.18 nM for FGFR1, 1.2 nM for FGFR2, 0.46 nM for FGFR3, 1.4 nM for FGFR4, and varying inhibitory effects on HDAC isoforms such as HDAC1 (1.3 nM), HDAC2 (1.6 nM), HDAC6 (2.6 nM), and HDAC8 (13 nM). This compound effectively induces apoptosis and causes cell cycle arrest at the G0/G1 phase. Additionally, HDAC-IN-50 decreases the expression of phosphorylated forms of FGFR1, ERK, and STAT3, indicating its potential applications in cancer research and therapy. -
VEGFR-2 Inhibitor
VEGFR-2-IN-52 is a potent inhibitor of Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2), demonstrating an IC50 of 191.1 nM. This compound effectively downregulates the expression of phosphorylated VEGFR-2, MMP9, and key signaling proteins p-ERK1/2 and p-MEK1. In addition to its cytotoxic effects, VEGFR-2-IN-52 induces apoptosis and promotes cell cycle arrest in the G0/G1 phase. Furthermore, it enhances reactive oxygen species (ROS) levels, making it valuable for research in cancer therapeutics and angiogenesis studies. -
EGFR2 Inhibitor
EGFR-IN-105 is a selective inhibitor of the EGFR2 receptor, with an IC50 value of 0.68 μM. This compound demonstrates significant anticancer activity by inducing apoptosis in cancerous cells, making it a valuable tool for investigating therapeutic strategies in pancreatic cancer research. Its specificity and potency position it as an important reagent for studies focused on targeting EGFR-related pathways in oncology. -
VEGFR/PARP Inhibitor
VEGFR/PARP-IN-1 is a dual inhibitor targeting Vascular Endothelial Growth Factor Receptor (VEGFR) and Poly(ADP-ribose) Polymerase (PARP), with IC50 values of 191 nM and 60.9 nM, respectively. This compound inhibits DNA damage repair mechanisms, induces apoptosis, and causes G2/M phase cell cycle arrest. It demonstrates significant antiproliferative activity against BRCA wild-type breast cancer cell lines, specifically MDA-MB-231 and MCF-7, with IC50 values of 4.1 μM and 3.5 μM, respectively. VEGFR/PARP-IN-1 is an effective antitumor and anti-metastatic agent, making it valuable for cancer research applications. -
Pan-Trk Inhibitor
Pan-Trk-IN-3 is a potent pan-Trk inhibitor that effectively targets TrkA, TrkB, and TrkC, along with various drug-resistant mutants, exhibiting IC50 values as low as 2 nM. This compound demonstrates significant antitumor activity and induces apoptosis in cancer cells. Pan-Trk-IN-3 is suitable for research applications focusing on cancer biology and therapeutic development aimed at overcoming Trk-related resistance mechanisms.
